scholarly journals Chronic B Cell Deficiency from Birth Prevents Age-Related Alterations in the B Lineage

2011 ◽  
Vol 187 (5) ◽  
pp. 2140-2147 ◽  
Author(s):  
Zohar Keren ◽  
Dana Averbuch ◽  
Gitit Shahaf ◽  
Simona Zisman-Rozen ◽  
Karin Golan ◽  
...  
Keyword(s):  
B Cell ◽  
Age Related ◽  
B Lineage ◽  
B Cell Deficiency

scholarly journals B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity

Nature ◽  
2021 ◽  
Author(s):  
Baihao Zhang ◽  
Alexis Vogelzang ◽  
Michio Miyajima ◽  
Yuki Sugiura ◽  
Yibo Wu ◽  
...  
Keyword(s):  
B Cell ◽  
Plasma Cells ◽  
Interleukin 10 ◽  
Fine Tuning ◽  
Tumour Immunity ◽  
Extracellular Milieu ◽  
Signalling Molecule ◽  
B Lineage ◽  
Inflammatory Macrophages ◽  
B Cell Deficiency

AbstractSmall, soluble metabolites not only are essential intermediates in intracellular biochemical processes, but can also influence neighbouring cells when released into the extracellular milieu1–3. Here we identify the metabolite and neurotransmitter GABA as a candidate signalling molecule synthesized and secreted by activated B cells and plasma cells. We show that B cell-derived GABA promotes monocyte differentiation into anti-inflammatory macrophages that secrete interleukin-10 and inhibit CD8+ T cell killer function. In mice, B cell deficiency or B cell-specific inactivation of the GABA-generating enzyme GAD67 enhances anti-tumour responses. Our study reveals that, in addition to cytokines and membrane proteins, small metabolites derived from B-lineage cells have immunoregulatory functions, which may be pharmaceutical targets allowing fine-tuning of immune responses.

Identification of 22 novel BTK gene variants in B cell deficiency with hypogammaglobulinemia

2021 ◽  
pp. 108788
Author(s):  
Monica T. Kraft ◽  
Regan Pyle ◽  
Xiangyang Dong ◽  
John B. Hagan ◽  
Elizabeth Varga ◽  
...  
Keyword(s):  
B Cell ◽  
Gene Variants ◽  
B Cell Deficiency

scholarly journals B-cell Deficiency: A De Novo IKZF1 Patient and Review of the Literature

2018 ◽  
Vol 28 (1) ◽  
pp. 53-56 ◽  
Author(s):  
QY Chen ◽  
XC Wang ◽  
WJ Wang ◽  
QH Zhou ◽  
DR Liu ◽  
...  
Keyword(s):  
B Cell ◽  
De Novo ◽  
Review Of The Literature ◽  
B Cell Deficiency

scholarly journals Early B cell factor: Regulator of B lineage specification and commitment

2008 ◽  
Vol 20 (4) ◽  
pp. 221-227 ◽  
Author(s):  
Kara Lukin ◽  
Scott Fields ◽  
Jacqueline Hartley ◽  
James Hagman
Keyword(s):  
B Cell ◽  
Lineage Specification ◽  
B Lineage ◽  
Early B Cell Factor

Transformation of murine bone marrow cells with combined v-raf-v-myc oncogenes yields clonally related mature B cells and macrophages

1990 ◽  
Vol 10 (7) ◽  
pp. 3562-3568
Author(s):  
M Principato ◽  
J L Cleveland ◽  
U R Rapp ◽  
K L Holmes ◽  
J H Pierce ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cells ◽  
B Cell ◽  
Cell Lines ◽  
Bone Marrow Cells ◽  
Hematopoietic Differentiation ◽  
Developmental Relationships ◽  
Murine Bone Marrow ◽  
B Lineage ◽  
Marrow Cells

Murine bone marrow cells infected with replication-defective retroviruses containing v-raf alone or v-myc alone yielded transformed pre-B cell lines, while a retroviral construct containing both v-raf and v-myc oncogenes produced clonally related populations of mature B cells and mature macrophages. The genealogy of these transformants demonstrates that mature myeloid cells were derived from cells with apparent B-lineage commitment and functional immunoglobulin rearrangements. This system should facilitate studies of developmental relationships in hematopoietic differentiation and analysis of lineage determination.

Should Adolescents with NHL Be Treated as Old Children or Young Adults?

Hematology ◽  
2007 ◽  
Vol 2007 (1) ◽  
pp. 297-303 ◽  
Author(s):  
John T. Sandlund
Keyword(s):  
Young Adults ◽  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lymphoblastic Lymphoma ◽  
Adolescents And Young Adults ◽  
Large B Cell Lymphoma ◽  
Age Related ◽  
Large B Cell

Abstract The SEER (Surveillance, Epidemiology, and End Results) data for the years 1975–1998 show that children with non-Hodgkin lymphoma (NHL) have a better treatment outcome than do adults. Many factors may contribute to this age-related difference. Some factors are related to the patient (e.g., drug distribution and clearance, performance status, compliance, sex) whereas others pertain to tumor histology and biology. The spectrum of NHL subtypes is well known to differ in children and adults. From ages 5 through 14 years, Burkitt lymphoma is the predominant histologic subtype, whereas diffuse large B-cell lymphoma is most common in the 15- to 29-year age range. Because different treatment strategies are often used in children and adults with NHL, the choice of therapy for adolescents and young adults (ages 15 through 29 years) is challenging and somewhat controversial. It is reasonable to consider pediatric strategies for some adolescents and very young adults with NHL, and pediatric strategies are currently used to treat adults with certain subtypes of NHL (Burkitt lymphoma, lymphoblastic lymphoma). However, the use of pediatric strategies in adults does not guarantee a comparable outcome, as illustrated by trials for adult lymphoblastic lymphoma. There is clearly a need for further biologic study of NHL in children, adolescents, and young adults. Age-related differences in tumor biology have been demonstrated in anaplastic large-cell lymphoma (ALCL) and diffuse large B-cell lymphoma (DLBCL). Additional biologic data will not only improve prognosis and treatment stratification but, more important, will lead to the identification of specific molecular targets for therapy.

scholarly journals B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells

Blood ◽  
1987 ◽  
Vol 70 (4) ◽  
pp. 1020-1034 ◽  
Author(s):  
FM Uckun ◽  
AS Fauci ◽  
NA Heerema ◽  
CW Song ◽  
SR Mehta ◽  
...  
Keyword(s):  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
Progenitor Cells ◽  
Stimulation Index ◽  
Receptor Expression ◽  
Cell Precursor ◽  
B Cell Growth Factor ◽  
B Lineage ◽  
B Cell Precursors

The purpose of this study was to analyze the expression of B cell growth factor (BCGF) receptors and to elucidate the biologic effects of biochemically purified natural BCGF at the B cell precursor stage of human B lineage lymphoid differentiation. The specific binding of radioiodinated high-mol-wt BCGF (125I-HMW-BCGF) and low-molecular-wt BCGF (125I-LMW-BCGF) to fresh marrow blasts from B cell precursor acute lymphoblastic leukemia (ALL) patients was initially investigated. The estimated number of radioiodinated BCGF molecules bound per blast ranged from undetectable to 24.3 X 10(3) for HMW-BCGF, and from 11.5 X 10(3) to 457.8 X 10(3) for LMW-BCGF. In 3H-TdR incorporation assays, 75% of cases showed a significant response to LMW-BCGF with a median stimulation index of 9.3. By comparison, only 33% of cases showed a significant response to HMW-BCGF with a median stimulation index of 2.4. Subsequently, B cell precursor colony assays were performed to assess and compare the biologic effects of BCGF on leukemic B lineage lymphoid progenitor cells. Among 28 cases studied, 57% responded to both HMW-BCGF and LMW-BCGF, 21% responded only to LMW-BCGF, and the remaining cases showed no proliferative response to either growth factor. The response patterns of virtually pure populations of FACS- sorted leukemic B cell precursors were essentially identical to the proliferative responses of unsorted leukemic B-cell precursors. Synergistic effects between HMW-BCGF and LMW-BCGF were observed in 80% of the cases that responded to both. The numbers of cell-bound radioiodinated BCGF molecules, the stimulation indices, as well as the number of B cell precursor colonies in BCGF-stimulated cultures showed a marked interpatient variation. Patients with structural chromosomal abnormalities (SCAs) involving 12p11–13 or patients with a Philadelphia chromosome showed a greater HMW-BCGF response at the level of leukemic progenitor cells than did other patients (P = .02). The LMW-BCGF response was significantly greater for patients with SCA than for patients without SCA (P = .04). The response of leukemic progenitor cells to HMW-BCGF or LMW-BCGF did not correlate with sex, age, disease status, FAB morphology, WBC at diagnosis, or immunophenotype. To our knowledge, this study represents the first detailed analyses of BCGF receptor expression and BCGF effects in B cell precursor ALL. The data presented provide direct evidence for the expression of functional receptors for both HMW-BCGF and LMW-BCGF in B cell precursor ALL.

Sign in / Sign up

Export Citation Format

Share Document